The DIANA Study: Continued Access to Darunavir/Ritonavir (DRV/r) and Long-Term Safety Follow-Up in HIV-1-Infected Pediatric Patients Aged 3 to < 18 Years.
Avy ViolariMaysseb MasenyaStephane BlancheSimon VanveggelVeerle HufkensPolan ChettyMagda OpsomerPublished in: Drug safety (2020)
ClinicalTrials.gov: NCT01138605/EudraCT number: 2009-017013-29; first submitted 8 April 2010.